scholarly journals Humoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease

2021 ◽  
Author(s):  
Trevor L Schell ◽  
Keith L Knutson ◽  
Sumona Saha ◽  
Arnold Wald ◽  
Hiep S Phan ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Vaccine Dose ◽  
The Third ◽  
Primary Series ◽  
Inflammatory Bowel

Summary: Herein, we evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with IBD. All patients were seropositive and had higher antibody concentrations after the third dose than after completion of the two-dose primary series.

scholarly journals Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease

2020 ◽  
pp. 205064062096461
Author(s):  
Ana-Marija Grišić ◽  
Maria Dorn-Rasmussen ◽  
Bella Ungar ◽  
Jørn Brynskov ◽  
Johan F K F Ilvemark ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
First Trimester ◽  
Interquartile Range ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic ◽  
Second Trimester ◽  
Third Trimester ◽  
The Third ◽  
Inflammatory Bowel

Background Infliximab therapy during pregnancy in inflammatory bowel disease is challenged by a dilemma between maintaining adequate maternal disease control while minimizing fetal infliximab exposure. We investigated the effects of pregnancy on infliximab pharmacokinetics. Methods The study population comprised 23 retrospectively identified pregnancies. Patients with inflammatory bowel disease were generally in clinical remission at pregnancy conception (74%) and received steady infliximab maintenance therapy (5 mg/kg q8w n = 17; q6w n = 4; q10w n = 1; 10 mg/kg q8w n = 1). Trough blood samples had been obtained in the same patients prior to pregnancy ( n = 119), the first trimester ( n = 16), second trimester ( n = 18), third trimester ( n = 7), and post-pregnancy ( n = 12). Data were analyzed using nonlinear mixed-effects population pharmacokinetic modelling. Results Dose-normalized infliximab concentrations were significantly higher during the second trimester (median 15 µg/mL/kg, interquartile range 10–21) compared to pre-pregnancy (7, 2–12; p = 0.003), the first trimester (9, 1–12; p = 0.04), or post-pregnancy (6, interquartile range 3–11; p > 0.05) in patients with inflammatory bowel disease. Similar trends were observed in the third trimester (13, 7–36; p > 0.05). A one-compartment model with linear elimination described the pharmacokinetics of infliximab (volume of distribution = 18.2 L; clearance 0.61 L/day). Maternal infliximab exposure was influenced by the second and third trimester of pregnancy and anti-infliximab antibodies, and not by pregnancy-imposed physiological changes in, for example, body weight or albumin. Infliximab clearance decreased significantly during the second and third trimesters by up to 15% as compared to pre- and post-pregnancy and the first trimester. The increased maternal infliximab exposure was weakly associated with lowered clinical disease activity. Pharmacokinetic model simulations of virtual patients indicated the increased maternal infliximab trough concentrations imposed by pregnancy will not completely counteract the decrease in infliximab concentration if therapy is paused in the third trimester. Conclusion Infliximab clearance decreases significantly in the second and third trimesters, leading to increasing maternal infliximab concentrations in any given regimen. Maternal infliximab levels may thus be maintained as constant in a de-intensified regimen by therapeutic drug monitoring guidance in inflammatory bowel disease.

INFLAMMATORY BOWEL DISEASE UNCLASSIFIED (IBDU): DESCRIPTION OF THE THIRD FORM OF IBD

2009 ◽  
Vol 41 ◽  
pp. S139
Author(s):  
S. Mazzuoli ◽  
N. Regano ◽  
A. Guglielmi ◽  
C. Panella ◽  
A. Di Leo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
The Third ◽  
Inflammatory Bowel

Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease

2020 ◽  
Vol 14 (12) ◽  
pp. 1780-1784 ◽  
Author(s):  
Sang Hyoung Park ◽  
Hyo Jong Kim ◽  
Chang Kyun Lee ◽  
Eun Mi Song ◽  
Sang-Bum Kang ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Adverse Events ◽  
Bowel Disease ◽  
Optimal Timing ◽  
Third Trimester ◽  
Serious Adverse Events ◽  
Bcg Vaccination ◽  
The Third ◽  
Gestational Week ◽  
Inflammatory Bowel

Abstract Backgrounds and Aims We aimed to evaluate the safety of Bacille Calmette–Guérin [BCG] vaccination in infants born to mothers receiving anti-tumour necrosis factor [anti-TNF] therapy for inflammatory bowel disease. Methods Adverse events of BCG vaccination were evaluated in 90 infants who were last exposed to anti-TNF agents at a median of gestational week 30. Results After receiving BCG vaccination at a median age of 6 months [range, 0.25–11 months], three infants [3.3%] showed injection site swelling, two of whom also showed axillar lymphadenopathy. The rates of adverse events were similar between infants who were last exposed to anti-TNF agents before the third trimester [n = 35] and those who were last exposed in the third trimester [n = 55] [2.9% vs 3.6%; p = 1.00]. All adverse events were spontaneously resolved and there were no serious adverse events such as active tuberculosis infection or death. Conclusions BCG vaccination after 6 months of age is of low risk in infants exposed to anti-TNF agents in utero.

scholarly journals Xanthogranulomatous cystitis associated with inflammatory bowel disease

2013 ◽  
Vol 4 (4) ◽  
pp. 91 ◽  
Author(s):  
Doreen E. Chung ◽  
Lesley K. Carr ◽  
Linda Sugar ◽  
Michelle Hladunewich ◽  
Leslie A. Deane
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
English Literature ◽  
Giant Cells ◽  
Multinucleated Giant Cells ◽  
Benign Condition ◽  
The Third ◽  
Xanthogranulomatous Inflammation ◽  
Inflammatory Bowel ◽  
Bladder Mass

Xanthogranulomatous inflammation is a benign condition characterizedby the presence of multinucleated giant cells, chronicinflammatory cells and lipid-laden macrophages, known as xanthomacells. Only 22 cases of xanthogranulomatous cystitis (XGC)have been reported in the Japanese and English literature. In thisreport, we describe the twenty-third case of XGC and the third caseassociated with inflammatory bowel disease (IBD). A 50-year-oldwoman with quiescent Crohn’s disease was incidentally foundto have a bladder mass on ultrasound. The lesion was resectedthrough a transurethral approach. Pathology demonstrated XGC.At 3 months post-resection, there was no evidence of recurrenceadjacent to the previous resection scar.

SEVERE GROWTH RETARDATION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE

PEDIATRICS ◽  
1970 ◽  
Vol 45 (3) ◽  
pp. 386-393
Author(s):  
Thomas D. McCaffery ◽  
Khosrow Nasr ◽  
A. M. Lawrence ◽  
Joseph B. Kirsner
Keyword(s):  
Inflammatory Bowel Disease ◽  
Growth Hormone ◽  
Corticosteroid Therapy ◽  
Growth Retardation ◽  
Bowel Disease ◽  
Gastrointestinal Symptoms ◽  
Hormone Response ◽  
The Third ◽  
Inflammatory Bowel ◽  
Severe Growth

From a group of 130 youngsters with inflammatory bowel disease, 22 were severely growth retarded (below the third percentile in height). This had preceded gastrointestinal symptoms for 1 to 11.4 years in 8 patients and corticosteroid therapy in 14. Endocrine evaluation demonstrated abnormally low 24-hour urinary gonadotropins in five of six patients more than age 16, and depressed growth hormone response to insulininduced hypoglycemia in 11 of 13 tested. Growth retardation in this group was attributed to a secondary hypopituitarism.

Intestinal Transplant Inflammation: the Third Inflammatory Bowel Disease

2016 ◽  
Vol 18 (11) ◽  
Author(s):  
Alexander Kroemer ◽  
Christopher Cosentino ◽  
Jason Kaiser ◽  
Cal S. Matsumoto ◽  
Thomas M. Fishbein
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
The Third ◽  
Inflammatory Bowel ◽  
Intestinal Transplant

scholarly journals P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S398-S399
Author(s):  
S Lin ◽  
C Bewshea ◽  
N Chanchlani ◽  
D Chee ◽  
R C Pollok ◽  
...  
Keyword(s):  
Public Health ◽  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
The Third ◽  
Health Measures ◽  
Spearman's Rho ◽  
Inflammatory Bowel ◽  
At Home

Abstract Background Given the existential threat from COVID-19 and the consequent restrictive public health measures it is perhaps unsurprising that SARS-CoV-2 infection has been linked to increases in rates of depression in the general population. Few studies, however have addressed anxiety and depression in patients with inflammatory bowel disease (IBD) during the COVID19 pandemic. We aimed to define, in patients with IBD treated with infliximab or vedolizumab and/or an immunomodulator, the prevalence, demographic and disease-related factors associated with depression and the effect of restrictive public health measures on rates of depression. Methods CLARITY IBD is a United Kingdom (UK) wide, multicentre, prospective observational cohort study investigating the impact of infliximab and vedolizumab and/or concomitant immunomodulators (thiopurines or methotrexate) on SARS-CoV-2 acquisition, illness, and immunity in patients with IBD. Patients were recruited between 22nd September and 23rd December 2020 and then assessed every 8 weeks. We measured depression using the 8-item Patient Health Questionnaire (PHQ-8). Secondary outcomes were anxiety and IBD-related quality of life assessed using the General Anxiety Disorder Assessment (GAD-7) and IBD-Control questionnaires, respectively. Multivariable logistic regression models were used to identify factors independently associated with depression at entry to the study. Baseline and paired responses during the third UK government’s stay-at-home lockdown order which commenced on the 4th January 2021 were compared using the Wilcoxon signed-rank test. Results The prevalence of depression at entry to the CLARITY study was 26% (1794/6933): 14% patients satisfied criteria for mild, 6% moderate and 5% severe depression. Depression scores were associated with anxiety (Spearman’s rho= 0.78, p<0.0001) and poorer IBD-Control-8 quality of life scores (Spearman’s rho=-0.67, p<0.0001). Multivariable analysis showed that vedolizumab (vs infliximab), steroid use, female sex, younger age, remaining at home, ulcerative colitis, comorbidity and higher income deprivation were associated with depression at entry to the study (Figure 1). Paired depression scores were unchanged between study entry and when assessed during the lockdown period (p=0.91). Conclusion Depression was negatively associated with infliximab therapy and was unchanged during the third UK stay-at-home lockdown. Longitudinal follow up in this cohort will allow us to determine whether COVID-19 vaccination influences depression and whether depression is linked to vaccine hesitancy or impaired serological responses to SARS-CoV-2 vaccination.

scholarly journals The Effect of Enteral Nutrition Support Rich in TGF-β in the Treatment of Inflammatory Bowel Disease in Childhood

Medicina ◽  
2019 ◽  
Vol 55 (10) ◽  
pp. 620 ◽  
Author(s):  
Mehmet Agin ◽  
Aylin Yucel ◽  
Meltem Gumus ◽  
Hasan Ali Yuksekkaya ◽  
Gokhan Tumgor
Keyword(s):  
Inflammatory Bowel Disease ◽  
Enteral Nutrition ◽  
Bowel Disease ◽  
Clinical Laboratory ◽  
Nutrition Support ◽  
Early Recovery ◽  
The Third ◽  
Laboratory Values ◽  
Inflammatory Bowel ◽  
Enteral Nutrition Support

Background and Objective: Malnutrition is a major complication of inflammatory bowel disease (IBD). Our aim of the study was to examine the effects of Modulen IBD supplementation, which was administered to IBD patients without limiting their daily diet in addition to medical treatment, on the clinical, laboratory, anthropometric values, and disease activities of these patients. Materials and Methods: Seventy three children with IBD were evaluated retrospectively. The cases were classified as those who had Crohn disease receiving (CD-M; n = 16) or not receiving Modulen IBD (CD; n = 19) and those who had ulcerative colitis receiving (UC-M; n = 13) or not receiving Modulen IBD (UC; n = 25). Disease activities, laboratory values, remission rates, and anthropometric measurements of the groups were compared. In addition to IBD treatment, Modulen IBD in which half of the daily calorie requirement was provided was given for eight weeks. Results: In the third month of treatment, 14 (88%) patients were in remission in CD-M group and eight (42%) patients were in remission in CD group. The height and weight z scores, which were low at the time of diagnosis, improved in the first week in CD-M group. Inflammatory parameters (UC) were significantly lower in the UC-M group compared to the UC group in first and third months. In the third month, eight (62%) patients in the UC-M group and four (16%) in the UC group were remitted clinically and in terms of laboratory values. Conclusions: TGF-β-rich enteral nutrition support in children with IBD is an easy, effective, and reliable approach. It was shown that TGF-β-rich enteral nutritional supplementation enabled the disease to enter the remission earlier, and contributed to the early recovery of weight and height scores.

scholarly journals Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease

2021 ◽  
Author(s):  
Dalin Li ◽  
Philip Debbas ◽  
Susan Cheng ◽  
Jonathan Braun ◽  
Dermot P.B. McGovern ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Gastrointestinal Symptoms ◽  
Vaccine Dose ◽  
Primary Vaccination ◽  
Similar Frequency ◽  
Post Vaccination ◽  
Symptom Profile ◽  
Symptom Frequency ◽  
Inflammatory Bowel

AbstractSymptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally of similar frequency, severity, and duration to those reported in the general population. The symptom profile after a 3rd mRNA vaccine dose in the predominantly immune-compromised IBD population is unknown. We aimed to assess symptomology after a 3rd or booster dose of mRNA vaccination in adults with IBD. We surveyed participants of the Coronavirus Risk Associations and Longitudinal Evaluation in IBD (CORALE-IBD) post-vaccination registry for symptom frequency and severity after a 3rd mRNA vaccine dose in an observational cohort study. In total, 524 participants (70% female, mean age 45 years) reported a third dose of mRNA vaccination through October 11, 2021. Overall, 41% reported symptoms after a third dose, with symptoms generally more frequent and more severe among participants younger than 55 years. The most frequent postvaccination symptoms were injection site pain (39%), fatigue or malaise (34%), and headache (23%). These symptoms were all less frequently reported after dose 3 than after dose 2. Gastrointestinal symptoms were reported by 8.8%, which was slightly more frequent than after dose 2 (7.8%). Those with severe symptoms after dose 2 were more likely to have severe symptoms after dose 3. These findings can reassure the IBD patient and provider communities that the likelihood and distribution of symptoms after a third mRNA vaccine dose are generally similar to those after a second dose, and that the frequency of postvaccination symptoms after dose 3 are generally lower than after dose 2.

Sign in / Sign up

Export Citation Format

Share Document